Patient Web Site | Site Map | Contact Us

Pharmacokinetics

CRESTOR: No CYP450 3A4 metabolism

In normal volunteers and in vitro — not metabolized by CYP450 3A4 to a clinically significant extent

CRESTOR has no clinically significant drug interaction with

¹

• The risk of myopathy may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir. The benefit of further alterations in lipid levels by the combined use of CRESTOR with fibrates or niacin should be carefully weighed against the potential risks of this combination. Combination therapy with CRESTOR and gemfibrozil should generally be avoided
• A large US pharmacokinetics study demonstrated an approximate 2-fold elevation in median exposure in Asian subjects compared to a Caucasian control group. CRESTOR dosage should be adjusted in Asian patients¹

Important safety information about CRESTOR

¹

Coadministration of CRESTOR to patients on stable warfarin therapy resulted in clinically significant rises in INR (>4, baseline 2 to 3). In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs.

Please see full Prescribing Information for CRESTOR.

CRESTOR was licensed from SHIONOGI & CO. LTD, Osaka, Japan.